Grofibrat (Fenofibrate)

Grofibrat is indicated for the treatment of several lipid abnormalities that increase cardiovascular risk.

• Management of hypertriglyceridemia, characterized by markedly elevated serum triglyceride concentrations, in adult patients.
• Treatment of mixed dyslipidemia, where high triglycerides coexist with low high‑density lipoprotein (HDL) cholesterol levels.
• Adjunct therapy for primary hypercholesterolemia, used together with diet, exercise, and statins to improve lipid profiles.
• Use in familial hypercholesterolemia when additional reduction of triglyceride‑rich lipoproteins is required.
• Reduction of severe hypertriglyceridemia to lower the risk of pancreatitis in high‑risk individuals.

Like other fibrates, Grofibrat may cause a range of adverse effects, most of which are mild and reversible, while rare events can be serious.

Common

• Nausea, abdominal discomfort, or dyspepsia, which are usually mild and resolve after continued therapy.
• Transient elevation of liver enzymes (ALT, AST) without clinical hepatitis.
• Headache or mild dizziness that does not interfere with daily activities.

Serious

• Myopathy or rhabdomyolysis, particularly when used together with statins or in patients with renal impairment.
• Significant hepatic injury manifested by marked elevation of transaminases and possible jaundice.
• Severe hypersensitivity reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Grofibrat, clinicians should evaluate patient history and laboratory values to identify conditions that may increase the risk of adverse outcomes.

• Assess baseline liver function tests; avoid use in patients with active hepatic disease.
• Evaluate renal function; dose adjustment may be needed in moderate to severe renal impairment.
• Review history of gallstones, as fibrates can increase biliary cholesterol saturation.
• Monitor for muscle symptoms, especially in patients receiving concomitant statins.
• Use caution in pregnant or breastfeeding women; safety data are limited.
• Consider potential drug interactions with anticoagulants, as fenofibrate may enhance anticoagulant effects.

Grofibrat can alter the pharmacokinetics of several medications; awareness of these interactions helps prevent toxicity or loss of efficacy.

Avoid

• Concurrent use with gemfibrozil, which markedly increases the risk of myopathy.
• Combination with strong CYP3A4 inhibitors (e.g., ketoconazole) that may raise fenofibrate plasma levels.

Use with caution

• Statins (especially simvastatin or lovastatin); monitor for signs of muscle toxicity.
• Anticoagulants such as warfarin; monitor INR more frequently.
• Oral hypoglycemic agents; fenofibrate may enhance glucose‑lowering effects.